Clinical trials: Sitagliptin, completed
Type 2 Diabetes
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Background: Dedicated renal hemodynamic and renal function studies are lacking for DPP-4 inhibitors in patients with Type 2 diabetes; accordingly little is known regarding the mechanisms mediating the renal effects of DPP-4…
- Trial name
- INDORSE (NCT02406443)
- Testing
- Sitaglitpin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Type 2 Diabetes Mellitus
A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)
A five-period crossover study to assess and compare the trough dipeptidyl peptidase IV (DPP-4) inhibition at 24-hours following the final morning dose for sitagliptin, saxagliptin and vildagliptin after 5 days of once daily…
- Trial name
- NCT01582308
- Testing
- Sitagliptin 100 mg, Saxagliptin 5 mg, Vildagliptin 50 mg
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastroparesis, Diabetes Mellitus
Effects of Sitagliptin on Gastric Emptying in Healthy Subjects
The purpose of this study is to determine the effects of the drug, sitagliptin, on the rate at which the stomach empties, and the release of gut hormones and blood glucose concentrations, after a mashed potato meal in healthy…
- Trial name
- NCT00501657
- Testing
- Sitagliptin
- Where
- Australia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Royal Adelaide Hospital
Polycystic Ovary Syndrome
The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome
Adults with abdominal obesity are at high risk for cardiovascular disease and also exhibit diminished growth hormone (GH) secretion; the latter further contributes to the development of visceral adiposity, impaired fibrinolysis…
- Trial name
- NCT02122380
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt University
Type 2 Diabetes
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the reduction in treatment burden during 12 weeks of trelagliptin administration in patients with type 2 diabetes on diet and exercise therapy only.
- Trial name
- TRENDS (NCT03014479)
- Testing
- Trelagliptin, Daily DPP-4 inhibitor
- Where
- 27 sites in Japan
- Volunteers
- 219 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-IV), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated…
- Trial name
- JANUB48 (NCT01334229)
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Laval University
Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 alone, in combination with sitagliptin, or in combination with K-833.
- Trial name
- NCT05900531
- Testing
- K-757, K-757 and open-label sitagliptin, K-757 and K-833
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- TriGemX Bio, Inc.
Diabetes
Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment
It is well established that inhibition of dipeptidyl peptidase (DPP)-IV reduces glucose levels and preserves pancreatic beta cell function in patients with type 2 diabetes.
- Trial name
- NCT01100125
- Testing
- sitagliptin, insulin dose increase
- Where
- 2 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Seoul National University Bundang Hospital
Type 2 Diabetes Mellitus
Effect of DPP4 Inhibition on Vasoconstriction
The purpose of this study is to understand how dipeptidyl peptidase IV (DPP4) inhibition in diabetics affects hemodynamic parameters and sympathetic activation in the setting of increasing concentrations of neuropeptide Y, an…
- Trial name
- NCT02639637
- Testing
- Sitagliptin, Neuropeptide Y, Enalaprilat
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt University
Type 2 Diabetes Mellitus
Initial Combination With Pioglitazone Study (0431-064)
A clinical study to evaluate the safety and efficacy of the initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes mellitus not on treatment with insulin or oral antihyperglycemic therapy.
- Trial name
- NCT00397631
- Testing
- sitagliptin 100 mg q.d./pioglitazone 30 mg q.d
- Volunteers
- 520 people
- Sponsor
- Merck Sharp & Dohme LLC
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124560
- Testing
- Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin
This study will assess the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and pharmacodynamics (explores what a drug does to the body) of single doses of JNJ-38431055, sitagliptin, and…
- Trial name
- NCT01054118
- Testing
- JNJ-38431055, Sitagliptin 100 mg, JNJ-38431055 + Sitagliptin 100 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)
The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in participants with moderate or severe renal insufficiency.
- Trial name
- NCT00509262
- Testing
- Sitagliptin, Glipizide
- Volunteers
- 426 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatitis, Diabetes
Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant
The purpose of the study is to test the effects of sitagliptin on the need for insulin (the hormone that lowers blood sugars) by patients who receive a pancreatectomy and islet autotransplant for chronic pancreatitis.
- Trial name
- NCT01186562
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- University of Minnesota
Type 2 Diabetes Mellitus
Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)
This study will assess the efficacy and safety of initial treatment with sitagliptin and metformin in patients with type 2 diabetes mellitus in China.
- Trial name
- NCT01076088
- Testing
- Sitagliptin 50 mg, Metformin 500 mg, Sitagliptin 100 mg
- Volunteers
- 744 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Add Glucokinase Activator to Target A1c
This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6…
- Trial name
- AGATA (NCT02405260)
- Testing
- TTP399 400 mg, TTP399 800 mg, Sitagliptin 100 mg
- Where
- 20 sites in United States
- Volunteers
- 190 people
- Sponsor
- vTv Therapeutics
Type 1 Diabetes, Hypoglycemia
Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery
Hypoglycaemia is a well-known complication of insulin treated diabetes. The counterregulatory response to hypoglycaemia, with glucagon as the most important mediator, is initially diminished within a few years of onset of Type 1…
- Trial name
- DARE (NCT01272583)
- Testing
- Sitagliptin
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Diabetes
Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination
It is well established that inhibition of dipeptidyl peptidase (DPP)-IV reduces glucose levels in both fasting and postprandial states and preserves pancreatic beta cell function in patients with type 2 diabetes.
- Trial name
- COSMETIC (NCT00969566)
- Testing
- sitagliptin, metformin
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Seoul National University Bundang Hospital
Diabete Mellitus, Type 2 Diabetes
Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes
This clinical trial was conducted at the National Diabetes Center for Treatment and Research, Mustansiriyah University, Baghdad (Sept 2024-May 2025).
- Conditions
- Diabete Mellitus, Type 2 Diabetes, Obesity Type 2 Diabetes Mellitus, Dyslipidemia in Patients With Diabetes Mellitus
- Trial name
- NCT07172269
- Testing
- Sitagliptin + Metformin, mangosteen supplement, Lifestyle Management
- Where
- Iraq
- Volunteers
- 58 people
- Sponsor
- Mais Qais Hbeeb
Diabetes Mellitus, Non-Insulin-Dependent
MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
The phase III clinical trial examines the efficacy, safety, and tolerability of the addition of MK0431/ONO-5435 to Japanese patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT00837577
- Testing
- Sitagliptin, Voglibose
- Volunteers
- 133 people
- Sponsor
- Merck Sharp & Dohme LLC